

Review of: "Immune response in suckling mice fed PBMCs harvested from adult mice and pulsed with Prevnar13: a pilot study"

Gergely Toldi¹

¹ University of Auckland

Potential competing interests: The author(s) declared that no potential competing interests exist.

Thank you for the opportunity to review this manuscript. It contains exciting data from a pilot study performed in mice, bringing valuable insight for the design of future experiments. The manuscript is succinct but overall well written. It would benefit from clarification of the following few minor points by the authors:

1. It is unclear on which day of life *S. pneumoniae* challenge was performed (PBMCs/vaccine was administered on Day 5. The manuscript states "Mice were subject to lethal infectious challenge 28 days after oral vaccination" which would bring us to Day 33 rather than "at an age of 35 days."
2. What was the positive control in Figure 2?
3. On Figure 3, the survival rate of the Prevenar-13 + PBMC group appears to be around 20% on Day 6 post challenge, which is contrast with "There was no difference in survival between groups and mortality was total". Are data available for this group from subsequent time points?
4. Finally, the Introduction refers to the "immaturity" of the neonatal immune system. This is more of a theoretical question, but in my view the neonatal immune system is not immature, rather, it is differently regulated than in older age. It is shaped for accommodating for the dual challenge a neonate faces after birth: fighting pathogens, but also learning to tolerate harmless environmental antigens.